Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;82(6):1471-1476.
doi: 10.1111/bcp.13077. Epub 2016 Sep 8.

UK medicines regulation: responding to current challenges

Affiliations
Review

UK medicines regulation: responding to current challenges

Natalie Richards et al. Br J Clin Pharmacol. 2016 Dec.

Abstract

The medicines regulatory environment is evolving rapidly in response to the changing environment. Advances in science and technology have led to a vast field of increasingly complicated pharmaceutical and medical device products; increasing globalization of the pharmaceutical industry, advances in digital technology and the internet, changing patient populations, and shifts in society also affect the regulatory environment. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices and blood products to protect and improve public health, and supports innovation through scientific research and development. It works closely with other bodies in a single medicines network across Europe and takes forward UK health priorities. This paper discusses the range of initiatives in the UK and across Europe to support innovation in medicines regulation. The MHRA leads a number of initiatives, such as the Innovation Office, which helps innovators to navigate the regulatory processes to progress their products or technologies; and simplification of the Clinical Trials Regulations and the Early Access to Medicines Scheme, to bring innovative medicines to patients faster. The Accelerated Access Review will identify reforms to accelerate access for National Health Service patients to innovative medicines and medical technologies. PRIME and Adaptive Pathways initiatives are joint endeavours within the European regulatory community. The MHRA runs spontaneous reporting schemes and works with INTERPOL to tackle counterfeiting and substandard products sold via the internet. The role of the regulator is changing rapidly, with new risk-proportionate, flexible approaches being introduced. International collaboration is a key element of the work of regulators, and is set to expand.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The three centres of the Medicines and Healthcare products Regulatory Agency
Figure 2
Figure 2
Falsified Medicines Directive logo for UK retailers

References

    1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 2016; 44 (Database Issue): D1054–68. - PMC - PubMed
    1. Torjesen I. Drug development: the journey of a medicine from lab to shelf. Pharmaceutical J 2015. [online]. URI: 20068196. Available at http://www.pharmaceutical‐journal.com/publications/tomorrows‐pharmacist/... (last accessed 27 June 2016).
    1. Office for Life Sciences [online]. Available at https://www.gov.uk/government/organisations/office‐for‐life‐sciences/about (last accessed 27 June 2016).
    1. Department of Health's agencies and partner organisations [online]. Available at https://www.gov.uk/government/publications/how‐to‐contact‐department‐of‐... (last accessed 27 June 2016).
    1. MHRA Innovation Office [online]. Available at https://www.gov.uk/government/groups/mhra‐innovation‐office#case‐studies (last accessed 27 June 2016).

MeSH terms

LinkOut - more resources